CFO
DXCM icon

Callan Family Office’s DexCom DXCM Stock Holding History

Callan Family Office’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Buy
6,452
+402
+7% +$26.8K 0.01% 862
2026
Q1 		$380K Sell
6,050
-7,491
-55% -$522K 0.01% 855
2025
Q4 		$899K Sell
13,541
-8,088
-37% -$523K 0.02% 579
2025
Q3 		$1.46M Sell
21,629
-2,203
-9% -$174K 0.05% 316
2025
Q2 		$2.08M Buy
23,832
+16,443
+223% +$1.29M 0.07% 267
2025
Q1 		$505K Buy
7,389
+4,328
+141% +$353K 0.04% 318
2024
Q4 		$238K Buy
+3,061
New +$227K 0.02% 558

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Callan Family Office's DXCM Position: Q2 2026 in Review

Callan Family Office increased its DexCom (DXCM) stake by 6.6% in Q2 2026, buying an estimated $26.8K and bringing the position to 6,452 shares worth $435K. The position accounts for 0.01% of the portfolio, ranked #862.

Callan Family Office first reported a position in DXCM in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.08M in Q2 2025. 976 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Callan Family Office held 6,452 shares of DexCom worth $435K as of Q2 2026.
  • Callan Family Office bought 402 DexCom shares in Q2 2026, an estimated $26.8K.
  • DexCom made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #862 holding.
  • Callan Family Office first reported a position in DexCom in Q4 2024 and has held it in 7 quarters since.
  • Callan Family Office's DexCom position peaked at $2.08M in Q2 2025.
  • 976 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.